

# Lack of Foxp3 function and expression in the thymic epithelium

Adrian Liston,<sup>1</sup> Andrew G. Farr,<sup>1,2</sup> Zhibin Chen,<sup>4</sup> Christophe Benoist,<sup>4</sup> Diane Mathis,<sup>4</sup> Nancy R. Manley,<sup>5</sup> and Alexander Y. Rudensky<sup>1,3</sup>

<sup>1</sup>Department of Immunology, <sup>2</sup>Department of Biological Structure, and <sup>3</sup>Howard Hughes Medical Institute, University of Washington School of Medicine, Seattle, WA 98195

<sup>4</sup>Department of Medicine, Joslin Diabetes Center, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215

<sup>5</sup>Department of Genetics, University of Georgia, Athens, GA 30602

**Foxp3 is essential for the commitment of differentiating thymocytes to the regulatory CD4<sup>+</sup> T (T reg) cell lineage. In humans and mice with a genetic Foxp3 deficiency, absence of this critical T reg cell population was suggested to be responsible for the severe autoimmune lesions. Recently, it has been proposed that in addition to T reg cells, Foxp3 is also expressed in thymic epithelial cells where it is involved in regulation of early thymocyte differentiation and is required to prevent autoimmunity. Here, we used genetic tools to demonstrate that the thymic epithelium does not express Foxp3. Furthermore, we formally showed that genetic abatement of *Foxp3* in the hematopoietic compartment, i.e. in T cells, is both necessary and sufficient to induce the autoimmune lesions associated with Foxp3 loss. In contrast, deletion of a conditional *Foxp3* allele in thymic epithelial cells did not result in detectable changes in thymocyte differentiation or pathology. Therefore, in mice the only known role for Foxp3 remains promotion of T reg cell differentiation within the T cell lineage, whereas there is no role for Foxp3 in thymic epithelial cells.**

## CORRESPONDENCE

Alexander Y. Rudensky:  
aruden@u.washington.edu

*FOXP3* was discovered through the genetic analysis of patients with the hereditary monogenic disorder immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. Concurrently, disruption of the murine homologue *Foxp3* was found to be the causal mutation underlying the *scurfy* phenotype. The lesions observed in mouse and man included lymphadenopathy and splenomegaly, exfoliative dermatitis and eczema, autoimmune thrombocytopenia, type 1 diabetes, and autoimmune thyroiditis (1–4). Despite the identification of the genetic basis of the disorder in humans and mice, its immunological mechanism has long been the subject of a great deal of controversy. Although several studies suggested that the autoimmune lesions in mice are mediated by T cells (5–9), early BM transplantation experiments showed that the transfer of mutant hematopoietic stem cells into lethally irradiated wild-type recipients by itself does not result in pathology (2). In agreement with these results, transplantation of mutant *Foxp3*<sup>3f</sup> thymi into

*nude* or SCID recipients resulted in the characteristic disease (10). Collectively, these studies implicated impaired differentiation of T cells in Foxp3-deficient thymic stroma as a cause of pathology. The evidence in favor of the latter possibility remained inconclusive, however, because the aforementioned inability of Foxp3 mutant BM-derived cells to induce disease in *Foxp3*<sup>3f</sup> → *Foxp3*<sup>mut</sup> recipients can be explained by surviving radio-resistant wild-type host T cells capable of providing protection. Indeed, the presence of as little as 3–5% of wild-type BM is sufficient to rescue the disease in mixed BM chimeras (11). Furthermore, the transfer of disease via thymic transplant into a lymphopenic host can be explained by the presence of pathogenic thymocytes within the transplanted thymus.

More recent studies have provided a radically different explanation for of the pathology associated with Foxp3 deficiency. Foxp3 was suggested to be a “master regulator” of CD4<sup>+</sup>CD25<sup>+</sup> T regulatory (T reg) cell differentiation because these cells fail to differentiate in the absence of Foxp3, and forced expression of Foxp3 facilitates differentiation of peripheral non-T reg cells into T reg cells (12–14).

Z. Chen's present address is Dept. of Microbiology and Immunology, University of Miami, Miami, FL 33136.

The online version of this article contains supplemental material.

Because transfection of *Foxp3* endows the transfected cells expressing high levels of *Foxp3* with suppressive properties (13, 14), and in mixed BM chimeras generated upon transferring of *Foxp3*<sup>-</sup> and *Foxp3*<sup>+</sup> BM into *Rag2*<sup>-/-</sup> recipients T reg cells differentiate only from the *Foxp3*<sup>+</sup> BM, a T cell-intrinsic role for *Foxp3*-mediated regulation of tolerance was proposed. This view was formally established by the observation of indistinguishable disease in mice with the germline- and CD4-Cre-mediated T cell lineage-restricted ablation of a conditional *Foxp3*<sup>Fllox</sup> allele (15).

However, a recent study by Chang et al. (16, 17) revived the old argument by raising an interesting possibility that *Foxp3* is expressed in the thymus not only in differentiating T reg cells but also in the thymic epithelium. It was further proposed that *Foxp3* expressed in the thymic epithelium plays an essential role in the regulation of double negative (DN) thymocyte maturation and that its dysregulation in the absence of *Foxp3* results in fatal autoimmunity. In agreement with this idea, *Foxp3*<sup>wt</sup> *Rag*<sup>-/-</sup> recipients reconstituted with *Foxp3*<sup>-</sup> BM did not manifest fatal autoimmunity (16).

To resolve this continuing controversy, we have used a genetic approach to revisit potential *Foxp3* expression and its role in the thymic epithelium. We found no evidence for *Foxp3* expression or function in the thymic epithelium in suppressing the autoimmune symptoms associated with *Foxp3* deficiency and in guiding early thymocyte differentiation. Our results demonstrate that *Foxp3* has a solely T cell-intrinsic function required to maintain tolerance and prevent autoimmunity.

## RESULTS AND DISCUSSION

### No detectable *Foxp3* protein expression in the thymic epithelium


Recently, apparent expression of *Foxp3* in the majority of thymic epithelial cells was observed in experiments using flow cytometry while a subset of thymic cortical epithelial cells was found positive for *Foxp3* by immunofluorescence (16). Because epithelial cells are notorious for a high degree of nonspecific antibody binding in flow cytometric assays and are tightly associated with thymocytes in situ, potentially leading to false positive results in immunofluorescence assays, we sought to reexamine *Foxp3* expression in thymic epithe-

lial cells and thymocytes by flow cytometric analysis of genetically marked *Foxp3*-expressing cells using knock-in mice harboring a *Foxp3*<sup>GFP</sup> reporter allele.

Previously, through examination of thymic tissue sections using immunofluorescence, we found *Foxp3*<sup>GFP</sup> protein predominantly expressed in the medullary region in the thymus with rare *Foxp3*<sup>+</sup> cells in the cortex (15). The cortical expression of GFP was previously ascribed to expression by the few CD4<sup>+</sup>CD8<sup>+</sup> double positive (DP) thymocytes that are GFP<sup>+</sup> by flow cytometry (15). To determine if this expression was due instead to epithelial cell expression of the *Foxp3*<sup>GFP</sup> allele, we performed flow cytometric analysis of purified CD45<sup>-</sup> thymic stroma from *Foxp3*<sup>GFP</sup> mice and found no expression of GFP (Fig. 1 A). For in situ analysis of epithelial cells, we crossed the *Foxp3*<sup>GFP</sup> allele into the *Rag2*<sup>-/-</sup> mouse line. Consistent with our previous studies, no expression of *Foxp3* was observed in thymocytes isolated from *Rag2*<sup>-/-</sup> *Foxp3*<sup>GFP</sup> mice (not depicted). This finding allowed us to examine *Foxp3* expression in thymic stromal cells using immunofluorescence in the absence of “contaminating” *Foxp3*-expressing thymocytes by examining GFP expression using anti-GFP antibody (not depicted) and polyclonal affinity-purified rabbit antibody specific for *Foxp3* (Fig. 1 B). We found no sign of *Foxp3* expression in *Rag*-deficient stroma above background fluorescence observed for *Foxp3*<sup>-</sup> mice, whereas *Foxp3* expression was readily detectable in control *Rag*-sufficient mice (Fig. 1 B). These data demonstrate that the thymic epithelium did not express detectable levels of *Foxp3* protein within the sensitivity limit of these assays.

### Disruption of *Foxp3* in thymocytes is necessary and sufficient to cause autoimmune syndromes

Although the aforementioned studies failed to detect *Foxp3* protein in thymic epithelial cells, it can be argued that our detection of *Foxp3* protein is not sufficiently sensitive. Thus, the possibility remained that low level of *Foxp3* expression in thymic epithelial cells at a certain stage of T cell differentiation is required for prevention of autoimmunity. We addressed this possibility by ablation of a conditional *Foxp3*<sup>Fllox</sup> allele using Cre recombinase expressed exclusively in thymic epithelial cells. Because the *Foxn1* gene is the highly specialized




**Figure 1. No expression of *Foxp3* in the thymic epithelium.** (A) Expression of GFP in CD45<sup>-</sup> thymic stroma from wild-type (shaded) and *Foxp3*<sup>GFP</sup> mice (line). Data is representative of four independent experiments. (B) Immunohistochemical analysis of *Foxp3* expression in the

thymus of *Foxp3*<sup>GFP</sup>, *Foxp3*<sup>GFP</sup>*Rag2*<sup>-/-</sup>, and *Foxp3*<sup>-</sup>*Rag*<sup>-/-</sup> mice. Thymic sections were stained with the affinity-purified rabbit anti-*Foxp3* antibody. Bar, 100  $\mu$ m.

regulator of thymic epithelial cell differentiation and is not expressed in BM-derived cells, we bred *Foxp3<sup>Flox</sup>* mice with mice harboring Cre recombinase knocked into the 3' untranslated region of the *Foxn1* locus (*Foxn1<sup>Cre</sup>*; unpublished data). The resulting *Foxp3<sup>Flox</sup> × Foxn1<sup>Cre</sup>* mice were examined for signs of lymphoproliferative autoimmune disease and compared with *Foxp3<sup>Flox</sup> × CD4-Cre* mice.

The interpretation of these experiments, however, was critically dependent on the specificity of CD4-Cre- and *Foxn1<sup>Cre</sup>*-mediated deletion. In this regard, it was proposed that the autoimmunity previously reported in *Foxp3<sup>Flox</sup> × CD4-Cre* mice (15) is due to CD4-Cre-mediated deletion of the *Foxp3* allele in a subset of CD4-expressing thymic epithelial cells. To directly address this issue, we first examined CD4 expression on CD45<sup>-</sup> thymic stromal cells using flow cytometry and failed to find CD4<sup>+</sup> thymic epithelial cells (Fig. 2 A). Next, we tested the cell type specificity of recombination mediated by CD4-Cre and *Foxn1<sup>Cre</sup>* using the Rosa26-stop<sup>Flox</sup>-YFP recombination reporter allele as a genetic fate-mapping tool. We found that CD4-Cre induced recombination in the majority of thymocytes, but no recombination was detectable in the CD45<sup>-</sup> thymic stroma (Fig. 2 A). On the contrary, *Foxn1<sup>Cre</sup>*-induced recombination occurred in the majority of CD45<sup>-</sup>G8.8<sup>+</sup> thymic epithelial cells, but not CD45<sup>-</sup>G8.8<sup>-</sup> stromal cells or thymocytes (Fig. 2 B). A comparable extent of *Foxp3* deletion in purified CD45<sup>-</sup>G8.8<sup>+</sup> thymic epithelial cells from *Foxp3<sup>Flox</sup> × Foxn1<sup>Cre</sup>* was confirmed by genomic PCR (not depicted). When the CD45<sup>-</sup>G8.8<sup>+</sup> population was subdivided according to the expression of UEA-1 or MHC class II, both subsets showed similar levels of Cre-mediated recombination (not depicted). *Foxn1<sup>Cre</sup>* was therefore active in the vast majority of thymic epithelial cells, but not fibroblasts or thymocytes. Importantly, *Foxp3<sup>Flox</sup> × Foxn1<sup>Cre</sup>* mice remained as healthy as *Foxp3<sup>WT</sup> × Foxn1<sup>Cre</sup>* littermates and showed no signs of T cell activation (not depicted), tissue pathology, or wasting disease (Fig. 2 C). In contrast, *Foxp3<sup>Flox</sup> × CD4-Cre* mice developed lethal autoimmune lesions indistinguishable from those in *Foxp3<sup>-/-</sup>* mice in full agreement with our previously reported observations (15). Thus, *Foxp3* gene ablation in thymic epithelium does not result in autoimmunity.

These results were further supported by our experiments using transfers of T cell-depleted *Foxp3<sup>-/-</sup>* and *Foxp3<sup>mut</sup>* BM, either separately or mixed at a 1:1 ratio into sublethally irradiated *Rag2<sup>-/-</sup>* recipients. All recipients of *Foxp3<sup>-/-</sup>* BM died by 6–7 wk of age from severe autoimmune disease, whereas recipients of *Foxp3<sup>mut</sup>* BM and mixed BM chimeras remained healthy (not depicted). Although donor BM was depleted of CD4<sup>+</sup> and CD8<sup>+</sup> T cells using magnetic bead sorting, it is impossible to formally exclude the possibility of a few pathogenic T cells remaining in the preparations of *Foxp3<sup>-/-</sup>* BM. In addition, our experiments also differed from those previously reported by Chang et al. in using mice harboring a *Foxp3<sup>-/-</sup>* allele generated through targeted mutagenesis and spontaneous *Foxp3<sup>sf</sup>* mutation, respectively. To definitively exclude these possible explanations for the contradictory results from




**Figure 2. Disruption of *Foxp3* in the T cell lineage is necessary and sufficient to cause autoimmune syndrome.** (A) No expression of CD4 in the CD45<sup>-</sup> thymic stroma. Left: expression of CD4 in wild-type CD45<sup>-</sup> thymic stroma. Thymic stromal cells were analyzed after incubation with anti-CD4 antibodies (solid line) or no antibody control (shaded). Right: expression of YFP in CD45<sup>-</sup> thymic stroma and CD45<sup>+</sup> thymocytes from wild-type (shaded) and Rosa-stop<sup>fl</sup>YFP × *CD4-Cre* (solid line) mice. Data representative of 11 and 3 experiments, respectively. (B) Expression of YFP from wild-type (shaded) and Rosa-stop<sup>fl</sup>YFP × *Foxn1<sup>Cre</sup>* (line) mice in CD45<sup>-</sup>G8.8<sup>+</sup> epithelium, CD45<sup>-</sup>G8.8<sup>-</sup> stroma, and thymocytes. Data is representative of three experiments. (C) Analysis of gross clinical signs and lung and skin histopathology in *Foxp3<sup>fl</sup> × Foxn1<sup>Cre</sup>* ( $n = 7$ ; no histological infiltrates at 4 or 9 wk of age, no visible disease at >16 wk of age), *Foxp3<sup>fl</sup> × CD4-Cre* ( $n = 6$ ; average life span 4 wk), *Foxp3<sup>-/-</sup>* ( $n = 7$ ; average life span 4 wk), and wild-type or *Foxp3<sup>fl</sup>* mice ( $n = 9$ ; no histological infiltrates or visible disease at >16 wk of age). Bar, 1 cm. For representative histology sections shown, lung and ear skin were taken from 4-wk-old male *Foxp3<sup>fl</sup>*, *Foxp3<sup>fl</sup> CD4-Cre*, and *Foxp3<sup>fl</sup> Foxn1<sup>Cre</sup>* mice. Arrows indicate inflammatory infiltrate. Bar, 100  $\mu$ m. (D) Disease onset in neonatal *Rag1<sup>-/-</sup>* mice reconstituted with *Foxp3* scurfy nude BM (■;  $n = 4$ ) or *Foxp3* wild-type nude BM (▲;  $n = 4$ ), and neonatal *Rag1<sup>-/-</sup>* *Foxp3* scurfy mice reconstituted with *Foxp3* scurfy nude BM (□;  $n = 5$ ) or *Foxp3* wild-type nude BM (●;  $n = 6$ ).

the two sets of BM transfer studies, we crossed the *Foxp3<sup>sf</sup>* allele to the *Foxn1*-deficient *nude* mice, which are characterized by an early block in thymic epithelium differentiation and thus lack mature T cells. As previously reported, *Foxp3<sup>sf</sup>* *nude* mice were not affected by the autoimmunity (2). Thus, we were able to transfer BM isolated from these disease-free mice into *Rag1<sup>-/-</sup>* recipients without the risk of contamination with mature pathogenic T cells. In these experiments, *Foxp3<sup>sf</sup>* *nude* BM reconstitution of neonatal *Rag1<sup>-/-</sup>* mice and *Foxp3<sup>sf</sup>**Rag1<sup>-/-</sup>* mice (serving as a positive control) resulted in identical lethal lymphoproliferative disease (Fig. 2 D). In contrast, control *Foxp3<sup>wt</sup>* *nude* BM transfers into either neonatal *Rag1<sup>-/-</sup>* or *Foxp3<sup>sf</sup>**Rag1<sup>-/-</sup>* did not result in disease (Fig. 2 D). The findings above demonstrate that genetic ablation of *Foxp3* in the thymic epithelium is neither necessary nor sufficient for the development of autoimmune disease.

**Distorted thymopoiesis associated with *Foxp3* deficiency is secondary to lymphoproliferative autoimmune syndrome**

Lack of autoimmunity in *Foxp3<sup>wt</sup>* *nude* → *Foxp3<sup>sf</sup>* *Rag1<sup>-/-</sup>* BM chimeras and in *Foxp3<sup>fllox</sup>* *Foxn1<sup>Cre</sup>* mice did not exclude the previously proposed role for expression of *Foxp3* in the thymic epithelium in normal thymopoiesis (16). Major thymic aberrations reported for *Foxp3* mutant mice include a decrease in thymic cellularity and in the proportion of CD4<sup>+</sup>CD8<sup>+</sup> DP thymocytes (16). To reexamine this possibility, we analyzed thymopoiesis in *Foxp3<sup>-/-</sup>*, *Foxp3<sup>fllox</sup>* CD4-Cre, and *Foxp3<sup>fllox</sup>* *Foxn1<sup>Cre</sup>* mice and found that both *Foxp3<sup>-/-</sup>* and the *Foxp3<sup>fllox</sup>* CD4-Cre mice showed reduced total thymic cellularity and a decrease in the percentage of CD4<sup>+</sup>CD8<sup>+</sup> DP thymocytes, whereas *Foxp3<sup>fllox</sup>* *Foxn1<sup>Cre</sup>* mice were identical to their wild-type littermates (Fig. 3, A and B). These results demonstrate that deletion of the *Foxp3* gene in thymic epithelial cells does not result in detectable changes in thymic T cell maturation, and that an apparent decrease in DP thymocyte subset size and in total thymocyte numbers is due to loss of *Foxp3* in thymocytes rather than in the thymic epithelium and is most likely secondary to the severe autoimmunity and cytokine storm common to the *Foxp3<sup>sf</sup>*, *Foxp3<sup>-/-</sup>*, and *Foxp3<sup>fl</sup>* CD4-Cre mice.


In addition to the aforementioned changes in thymocyte subsets, an expansion of DN1 (CD44<sup>+</sup>CD25<sup>-</sup>) cells was reported for both *Foxp3<sup>sf</sup>* and *Foxp3<sup>sf</sup>* *Rag2<sup>-/-</sup>* mice (16). To examine this phenomenon, we first analyzed the composition of DN thymocyte subsets in *Foxp3<sup>-/-</sup>*, *Foxp3<sup>fl</sup>* CD4-Cre, and *Foxp3<sup>fl</sup>* *Foxn1<sup>Cre</sup>* mice. The relative size of the DN1-4 thymocyte subsets was not altered in *Foxp3<sup>fl</sup>* *Foxn1<sup>Cre</sup>* as compared with control mice; however, we found relative increases in the DN1 subset in *Foxp3<sup>-/-</sup>* and *Foxp3<sup>fl</sup>* CD4-Cre mice (Fig. 3, C and D). To determine whether this is a cell-intrinsic defect in developing thymocytes, we analyzed DN thymocyte subsets in disease-free *Foxp3<sup>-/-</sup>**Rag2<sup>-/-</sup>* and control *Foxp3<sup>wt</sup>**Rag2<sup>-/-</sup>* littermates. No differences in the relative sizes of DN1, DN2, and DN3 subsets were detected in these mice (Fig. 4, A and B). To exclude the possibility that very few thymic epithelial cells escaping Cre-mediated deletion in *Foxp3<sup>fllox</sup>* × *Foxn1<sup>Cre</sup>* mice are capable of supporting normal



**Figure 3. Distorted thymopoiesis is dependent on *Foxp3* loss in the T cell lineage.** Thymopoiesis was assessed by examining total thymus cellularity and by flow cytometric analysis of thymocyte subsets. (A) Representative CD4 and CD8 thymocyte profiles for wild-type, *Foxp3*-deficient, *Foxp3<sup>fl</sup>* *CD4-Cre*, and *Foxp3<sup>fl</sup>* *Foxn1<sup>Cre</sup>* mice. Average thymus cellularity (mean ± SD) is shown below each graph. (B) Percentages of thymocytes in CD4<sup>-</sup>CD8<sup>-</sup> DN, CD4<sup>+</sup>CD8<sup>+</sup> DP, CD4<sup>+</sup> single positive, and CD8<sup>+</sup> single positive subsets. Each data point represents a single mouse. (C) Representative flow cytometric profiles of DN thymocyte subsets and (D) percentages of DN1, DN2, DN3, and DN4 subsets in wild-type, *Foxp3*-deficient, *Foxp3<sup>fl</sup>* *CD4-Cre*, and *Foxp3<sup>fl</sup>* *Foxn1<sup>Cre</sup>* mice.

thymocyte development, we generated an additional set of BM chimeras by transferring wild-type BM into *Foxp3<sup>-/-</sup>**Rag2<sup>-/-</sup>* and *Foxp3<sup>wt</sup>**Rag2<sup>-/-</sup>* recipients. The maturation of wild-type thymocytes was not different in the two sets





**Figure 4. *Foxp3* deficiency does not affect early thymopoiesis in disease-free *Rag*-deficient mice.** (A) Representative flow cytometric analysis of DN1, DN2, DN3, and DN4 thymocyte subsets and (B) their percentages in *Rag2*<sup>-/-</sup> and *Foxp3*-deficient *Rag2*<sup>-/-</sup> mice. Each point represents a single mouse ( $n = 5$ ). No statistically significant differences were observed between two groups of mice.

of chimeric mice (Fig. S1, available at <http://www.jem.org/cgi/content/full/jem.20062465/DC1>). Together with the absence of expression of *Foxp3* in DN thymocytes, these experiments show that the changes in DN thymocyte maturation observed in *Foxp3* mutant mice are secondary effects of massive peripheral T cell activation.

Collectively, our data demonstrates that the thymic epithelium does not express detectable amounts of *Foxp3* protein, and that there are no measurable adverse effects on immunological tolerance attributable to *Foxp3* deficiency in

thymic stromal cells or in other radiation-resistant nonhematopoietic cells. This conclusion is strongly supported by the lack of autoimmune manifestations and changes in thymocyte maturation upon *Foxn1*-Cre-mediated ablation of a conditional *Foxp3* allele in the thymic epithelium. In contrast, in control experiments, *Foxp3* ablation in the T cell lineage resulted in lethal autoimmune pathology typical of germline *Foxp3* mutation, as previously reported. In full agreement with these data are the results of the BM transfer experiments, which showed that *Foxp3* deficiency in hematopoietic cells is solely responsible for autoimmunity, and that perturbed thymocyte subsets in *Foxp3*-deficient mice are an indirect consequence of pathology. Thus, in mice the only known role for *Foxp3* remains promotion of T reg cell differentiation within the T cell lineage.

#### MATERIALS AND METHODS

**Mice.** *Foxp3*<sup>-</sup> (14), *Foxp3*<sup>fl</sup> (14), *Foxp3*<sup>GFP</sup> (15), *CD4*-Cre (18), *Foxn1*<sup>ex9cre</sup> (unpublished data; Cre was inserted along with an internal ribosome entry site into the 3' untranslated region of the *Foxn1* gene), *ROSA*-stop<sup>fl</sup>-YFP (19), *Foxp3*<sup>fl</sup>, nude, *Rag1*<sup>-/-</sup>, and *Rag2*<sup>-/-</sup> mice have all been backcrossed to the B6 background. B6 *Foxp3*<sup>fl</sup> mice were backcrossed either to the B6 nude or B6 *Rag1*<sup>-/-</sup> backgrounds two generations to produce *Foxp3*<sup>fl</sup> nude and *Foxp3*<sup>fl</sup> *Rag1*<sup>-/-</sup> strains. BM chimeras were constructed using  $7 \times 10^6$  BM cells/recipient harvested from athymic nude male mice with or without the *Foxp3*<sup>fl</sup> mutation and injected i.p. into neonatal (2–3 d) *Rag1*<sup>-/-</sup> with or without the *Foxp3*<sup>fl</sup>. Experimental mice were age and sex matched and housed in specific pathogen-free conditions. Disease incidence was monitored by frequent visual observation, and postmortem histological analysis of the tissues was performed using hematoxylin and eosin staining (Histology Consultation Services). All mice were used in accordance with guidelines from the Institutional Animal Care Committee of the University of Washington.

**Flow cytometry and immunofluorescence.** 5–10-wk-old mice were analyzed using the following antibodies: CD45-APC, I-A<sup>b</sup>-PE, CD4-PE-Cy7, CD44-PE, CD8-PerCP, CD25-APC, CD8-FITC, CD4-PerCP, and UEA-1 biotin, followed by SAV-PerCP (all from BD Biosciences) and G8.8 supernatant conjugated to Alexa 647. Thymic stroma preparations were enriched from three to six pooled thymi from 5–10-wk-old mice as described previously (20). After enzymatic enrichment, CD45<sup>-</sup> thymic stromal cells were purified using CD45 microbeads (Miltenyi Biotec) and the AutoMACS system (Miltenyi Biotec) as per the manufacturer's recommendations before flow cytometric analysis (21). Thymic sections were prepared and stained as described previously (22) using rabbit polyclonal IgG anti-*Foxp3* antibodies (14), followed by Alexa 546-conjugated goat anti-rabbit IgG. Images were acquired using a Leica SP1/MP confocal microscope.

**Online supplemental material.** Fig. S1 shows early thymopoiesis for wild-type BM-derived thymocytes developing in *Foxp3*-sufficient and *Foxp3*-deficient hosts assessed by CD44/CD25 flow cytometric profiles of CD4<sup>-</sup>CD8<sup>-</sup> thymocytes 4 wk after BM transfer. Fig. S1 is available at <http://www.jem.org/cgi/content/full/jem.20062465/DC1>.

We thank K. Forbush, L. Karpik, and T. Chu for coordinating mouse colonies.

This work was supported by grants from the National Institutes of Health (NIH) and the Juvenile Diabetes Research Foundation. A. Liston is an Abbot Research Fellow-Irvington Fellow, and Z. Chen was supported by an NIH T32 Training Grant. A.Y. Rudensky is a Howard Hughes Medical Institute investigator.

The authors have no conflicting financial interests.

Submitted: 27 November 2006

Accepted: 14 February 2007

## REFERENCES

- Wildin, R.S., S. Smyk-Pearson, and A.H. Filipovich. 2002. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. *J. Med. Genet.* 39:537–545.
- Godfrey, V.L., J.E. Wilkinson, E.M. Rinchik, and L.B. Russell. 1991. Fatal lymphoreticular disease in the scurfy (sf) mouse requires T cells that mature in a thymic environment: potential model for thymic education. *Proc. Natl. Acad. Sci. USA.* 88:5528–5532.
- Bennett, C.L., and H.D. Ochs. 2001. IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. *Curr. Opin. Pediatr.* 13:533–538.
- Ferguson, P.J., S.H. Blanton, F.T. Saulsbury, M.J. McDuffie, V. Lemahieu, J.M. Gastier, U. Francke, S.M. Borowitz, J.L. Sutphen, and T.E. Kelly. 2000. Manifestations and linkage analysis in X-linked autoimmunity-immunodeficiency syndrome. *Am. J. Med. Genet.* 90:390–397.
- Godfrey, V.L., J.E. Wilkinson, and L.B. Russell. 1991. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. *Am. J. Pathol.* 138:1379–1387.
- Chatila, T.A., F. Blaeser, N. Ho, H.M. Lederman, C. Voulgaropoulos, C. Helms, and A.M. Bowcock. 2000. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic dysregulation syndrome. *J. Clin. Invest.* 106:R75–R81.
- Clark, L.B., M.W. Appleby, M.E. Brunkow, J.E. Wilkinson, S.F. Ziegler, and F. Ramsdell. 1999. Cellular and molecular characterization of the scurfy mouse mutant. *J. Immunol.* 162:2546–2554.
- Blair, P.J., S.J. Bultman, J.C. Haas, B.T. Rouse, J.E. Wilkinson, and V.L. Godfrey. 1994. CD4+CD8– T cells are the effector cells in disease pathogenesis in the scurfy (sf) mouse. *J. Immunol.* 153:3764–3774.
- Zahorsky-Reeves, J.L., and J.E. Wilkinson. 2001. The murine mutation scurfy (sf) results in an antigen-dependent lymphoproliferative disease with altered T cell sensitivity. *Eur. J. Immunol.* 31:196–204.
- Godfrey, V.L., B.T. Rouse, and J.E. Wilkinson. 1994. Transplantation of T cell-mediated, lymphoreticular disease from the scurfy (sf) mouse. *Am. J. Pathol.* 145:281–286.
- Smyk-Pearson, S.K., A.C. Bakke, P.K. Held, and R.S. Wildin. 2003. Rescue of the autoimmune scurfy mouse by partial bone marrow transplantation or by injection with T-enriched splenocytes. *Clin. Exp. Immunol.* 133:193–199.
- Khattari, R., T. Cox, S.A. Yasayko, and F. Ramsdell. 2003. An essential role for Scurfin in CD4+CD25+ T regulatory cells. *Nat. Immunol.* 4:337–342.
- Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. *Science.* 299:1057–1061.
- Fontenot, J.D., M.A. Gavin, and A.Y. Rudensky. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. *Nat. Immunol.* 4:330–336.
- Fontenot, J.D., J.P. Rasmussen, L.M. Williams, J.L. Dooley, A.G. Farr, and A.Y. Rudensky. 2005. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. *Immunity.* 22:329–341.
- Chang, X., J.X. Gao, Q. Jiang, J. Wen, N. Seifers, L. Su, V.L. Godfrey, T. Zuo, P. Zheng, and Y. Liu. 2005. The Scurfy mutation of FoxP3 in the thymus stroma leads to defective thymopoiesis. *J. Exp. Med.* 202:1141–1151.
- Chang, X., P. Zheng, and Y. Liu. 2006. FoxP3: a genetic link between immunodeficiency and autoimmune diseases. *Autoimmun. Rev.* 5:399–402.
- Wolfer, A., T. Bakker, A. Wilson, M. Nicolas, V. Ioannidis, D.R. Littman, P.P. Lee, C.B. Wilson, W. Held, H.R. MacDonald, and F. Radtke. 2001. Inactivation of Notch 1 in immature thymocytes does not perturb CD4 or CD8T cell development. *Nat. Immunol.* 2:235–241.
- Srinivas, S., T. Watanabe, C.S. Lin, C.M. William, Y. Tanabe, T.M. Jessell, and F. Costantini. 2001. Cre reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. *BMC Dev. Biol.* 1:4.
- Dooley, J., M. Erickson, and A.G. Farr. 2005. An organized medullary epithelial structure in the normal thymus expresses molecules of respiratory epithelium and resembles the epithelial thymic rudiment of nude mice. *J. Immunol.* 175:4331–4337.
- Gray, D.H., A.P. Chidgey, and R.L. Boyd. 2002. Analysis of thymic stromal cell populations using flow cytometry. *J. Immunol. Methods.* 260:15–28.
- Lehar, S.M., J. Dooley, A.G. Farr, and M.J. Bevan. 2005. Notch ligands Delta 1 and Jagged1 transmit distinct signals to T-cell precursors. *Blood.* 105:1440–1447.